NAT2 and tuberculosis: Our aim is to explore whether the NAT2 genotype can be used to predict not only the risk, but also the timing of ATDH onset, thereby improving the early identification of patients at risk and supporting genotype-guided treatment adjustments, thereby optimizing both the safety and efficacy of anti-TB therapy.